Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Paolo Tarantino(Harvard University), Sara M. Tolaney(Harvard University), Carey K. Anders(Duke University), Melissa E. Hughes(Dana-Farber Cancer Institute), Janet Files(Dana-Farber Cancer Institute), David L. Rimm(Yale University), Tianyu Li(Dana-Farber Cancer Institute), Andrew D. Cherniack(Broad Institute), Nay Chan(Yale University), Nancy U. Lin(Dana-Farber Cancer Institute), Rinath Jeselsohn(Dana-Farber Cancer Institute), Stefania Morganti(Broad Institute), Alyssa Pereslete(Florida International University), Laura Alder(Duke Medical Center), Heather Moore(Clinical Research Institute), Kalie Smith(Dana-Farber Cancer Institute), Deborah Dillon(Harvard University), Hersh Gupta(Dana-Farber Cancer Institute), Yvonne Li(Broad Institute), Aleix Prat(Hospital Clínic de Barcelona), Laura Noteware, Kerry Sendrick(Dana-Farber Cancer Institute), Ross J. Kusmick(Dana-Farber Cancer Institute), Simone Buck(Dana-Farber Cancer Institute), Giuseppe Curigliano(European Institute of Oncology), Amanda Van Swearingen, Sarah Sammons(Dana-Farber Cancer Institute)
Cited by 11
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Comprehensive molecular profiling of lung adenocarcinoma
|Nature|2014|5.9k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k